伊藤　幸裕

2006年 3月　名古屋市立大学薬学部薬学科　卒業
2008年 3月　名古屋市立大学大学院薬学研究科　創薬生命科学専攻　博士前期課程修了
2010年 4月　日本学術振興会特別研究員（DC2）
2011年 3月　東京大学大学院薬学系研究科　分子薬学専攻　博士課程修了　博士（薬学）
2011年 4月　東京大学分子細胞生物学研究所　博士研究員
2011年 5月　スクリプス研究所　博士研究員
2012年 4月　京都府立医科大学大学院医学研究科 学内講師
2015年 4月　京都府立医科大学大学院医学研究科 講師
2019年 4月　京都府立医科大学大学院医学研究科 准教授
2019年 8月　大阪大学産業科学研究所 招へい准教授（兼務）
2020年 6月　大阪大学産業科学研究所 准教授
2020年 6月　京都府立医科大学大学院医学研究科 客員講師（兼務）
現在に至る

1. 第14回バイオ関連化学シンポジウム　講演賞　2020年9月．
2. ENT M Dr.浅野登＆暉子基金医学基礎研究助成事業　奨励賞　2019年11月.
3. 2018年度有機合成化学協会大正製薬研究企画賞　2018年12月.
4. 2019年度日本薬学会奨励賞　2018年11月.
5. 平成27年度日本薬学会メディシナルケミストリーシンポジウム優秀賞 　2015年11月.
6. 平成26年度CREST分子技術ライジング・スター賞受賞　2015年2月.
7. 上原記念生命科学財団海外留学助成リサーチフェローシップ（京都府立医大採用に伴い辞退） 2011年12月.
8. 第8回次世代を担う有機化学シンポジウム優秀発表賞、日本薬学会化学系薬学部会、2010年5月.
9. 日本学生支援機構大学院生第一種奨学金　特に優れた業績による返還免除　2008年.

1. Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, Yuri Takada, Tetsuya Iida, Makoto Oba, Yukihiro Itoh, Takayoshi Suzuki. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). Chemical Communications, in press 2022.
2. Muthuraj Prakash, Yukihiro Itoh, Yoshie Fujiwara, Yukari Takahashi, Yuri Takada, Paolo Mellini, Elghareeb E Elboray, Mitsuhiro Terao, Yasunobu Yamashita, Chika Yamamoto, Takao Yamaguchi, Masayuki Kotoku, Yuki Kitao, Ritesh Singh, Rohini Roy, Satoshi Obika, Makoto Oba, Dan Ohtan Wang, Takayoshi Suzuki. Identification of Potent and Selective Inhibitors of Fat Mass Obesity-Associated Protein Using a Fragment-Merging Approach. Journal of Medicinal Chemistry, 64, 15810-15824, 2021.
3. Takashi Kurohara, Keita Tanaka, Daisuke Takahashi, Satoshi Ueda, Yasunobu Yamashita, Yuri Takada, Hirokazu Takeshima, Shengwang Yu, Yukihiro Itoh, Koji Hase, Takayoshi Suzuki. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group. ChemBioChem, 22, 3158-3163, 2021.
4. Tetsuya Iida, Yukihiro Itoh, Yukari Takahashi, Yasunobu Yamashita, Takashi Kurohara, Yuka Miyake, Makoto Oba, Takayoshi Suzuki. Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5C Degraders. ChemMedChem 16, 1609-1618, 2021.
5. Yuka Miyake, Yukihiro Itoh, Yoshinori Suzuma, Hidehiko Kodama, Shusaku Uchida, Takayoshi Suzuki. Metalloprotein-Catalyzed Click Reaction for In Situ Generation of a Potent Inhibitor. ACS Catalysis, 10, 5383–5392, 2020.
6. Shusuke Ogihara, Toru Komatsu, Yukihiro Itoh, Yuka Miyake, Takayoshi Suzuki, Kouichi Yanagi, Yusuke Kimura, Tasuku Ueno, Kenjiro Hanaoka, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano, Yasuteru Urano. Metabolic-Pathway-Oriented Screening Targeting S-Adenosyl-l-methionine Reveals the Epigenetic Remodeling Activities of Naturally Occurring Catechols. Journal of the American Chemical Society, 142, 21–26, 2020.
7. Keng Yoon Yeong, Kooi Yeong Khaw, Yukari Takahashi, Yukihiro Itoh, Vikneswaran Murugaiyah, Takayoshi Suzuki. Discovery of gamma-mangostin from Garcinia mangostana as a potent and selective natural SIRT2 inhibitor. Bioorganic Chemistry, 94, 103403, 2020.
8. Paolo Mellini, Yukihiro Itoh, Elghareeb E. Elboray, Hiroki Tsumoto, Ying Li, Miki Suzuki, Yukari Takahashi, Toshifumi Tojo, Takashi Kurohara, Yuka Miyake, Yuri Miura, Yuki Kitao, Masayuki Kotoku, Tetsuya Iida, Takayoshi Suzuki. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the “Selectivity Pocket”, Substrate-Binding Site, and NAD+-Binding Site. Journal of Medicinal Chemistry, 62, 5844-5862, 2019.
9. Pattaporn Jaikhan, Benjaporn Buranrat, Yukihiro Itoh, Jiranan Chotitumnavee, Takashi Kurohara, Takayoshi Suzuki. Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors. Bioorganic & Medicinal Chemistry Letters, 29, 1173-1176, 2019.
10. Yuka Miyake, Yukihiro Itoh, Atsushi Hatanaka, Yoshinori Suzuma, Miki Suzuki, Hidehiko Kodama, Yoshinobu Arai, Takayoshi Suzuki. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy. Bioorganic & Medicinal Chemistry, 27, 1119-1129, 2019.
11. Yukihiro Itoh, Yusuke, Nakashima, Shuichiro Tsukamoto, Takashi Kurohara, Miki Suzuk,Yoshitake Sakae, Masayuki Oda, Yuko Okamoto, Takayoshi Suzuki. N+-C-H…O Hydrogen bonds in protein-ligand complexes. Sci. Rep. 9, 767, 2019.
12. Yusuke Ota, Arisa Nakamura, Elghareeb E. Elboray, Yukihiro Itoh, Takayoshi Suzuki. Design, synthesis, and biological evaluation of a conjugate of 5-fluorouracil and an LSD1 inhibitor. Chemical & Pharmaceutical Bulletin, 66, 192-195, 2019.
13. Yusuke Ota, Taeko Kakizawa, Yukihiro Itoh, Takayoshi Suzuki. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures. Molecules, 23, 1099, 2018.
14. Shuichiro Tsukamoto, Yoshitake Sakae, Yukihiro Itoh, Takayoshi Suzuki, Yuko Okamoto. Computational analysis for selectivity of histone deacetylase inhibitor by replica-exchange umbrella sampling molecular dynamics simulations. The Journal of Chemical Physics, 148, 125102, 2018.
15. Yukihiro Itoh, Miki Suzuki. Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors. Bioorganic & Medicinal Chemistry Letters, 28, 2723-2727, 2018.
16. Yosuke Ota, Shin Miyamura, Misaho Araki, Yukihiro Itoh, Shusuke Yasuda, Mitsuharu Masuda, Tomoyuki Taniguchi, Yoshihiro Sowa, Toshiyuki Sakai, Kenichiro Itami, Junichiro Yamaguchi, Takayoshi Suzuki. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.Bioorganic & Medicinal Chemistry, 26, 775-785, 2018.
17. Taeko Kakizawa, Yusuke Ota, Yukihiro Itoh, Takayoshi Suzuki. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Bioorganic & Medicinal Chemistry Letters, 28, 167-169, 2018.
18. Paolo Mellini, Yukihiro Itoh, Hiroki Tsumoto, Ying Li, Miki Suzuki, Natsu ko Tokuda, Taeko Kakizawa, Yuri Miura, Jun Takeuchi, Maija Lahtela-Kakkonene Takayoshi Suzuki. Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, “selectivity pocket” and NAD+-binding site. Chemical Science 8, 6400-6408, 2017.
19. Keiichiro Okuhira, Takuji Shoda, Risa Omura, Nobumichi Ohoka, Takayuki Hattori, Norihito Shibata, Yosuke Demizu, Ryo Sugihara, Asato Ichino, Haruka Kawahara, Yukihiro Itoh, Minoru Ishikawa, Yuichi Hashimoto, Masaaki Kurihara, Hiroyuki Saito, Mikihiko Naito. Targeted degradation of proteins localized in subcellular compartments by hybrid small molecules. Molecular pharmacology, 91, 159-166, 2017.
20. Yosuke Ota, Yukihiro Itoh, Asako Kaise, Kiminori Ohta, Yasuyuki Endo, Mitsuharu Masuda, Yoshihiro Sowa, Toshiyuki Sakai, Takayoshi Suzuki. Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen. Angewandte Chemie International Edition, 55, 16115-161118, 2016.
21. Shin Miyamura, Misaho Araki, Yosuke Ota, Yukihiro Itoh, Shusuke Yasuda, Mitsuharu Masuda, Tomoyuki Taniguchi, Yoshihiro Sowa, Toshiyuki Sakai, Takayoshi Suzuki, Kenichiro Itami, Junichiro Yamaguchi. C-H Activation Enables Rapid Structure-Activity Relationship Study of Arylcylclopropyl Amines for Potent and Selective LSD1 Inhibitors. Organic & Biomolecular Chemistry 14, 8576-8585, 2016.
22. Fumihiro Higuchi, Shusaku Uchida, Hirotaka Yamagata, Naoko Abe-Higuchi, Teruyuki Hobara, Kumiko Hara, Ayumi Kobayashi, Tatsushi Shintaku, Yukihiro Itoh, Takayoshi Suzuki, Yoshifumi Watanabe. Hippocampal microRNA-124 enhances chronic stress resilience in mice. Journal of Neuroscience, 36, 7253-7267, 2016.
23. Yukihiro Itoh, Miki Suzuki, Taiji Matsui, Yusuke Ota, Zi Hui, Kazunori Tsubaki, Takayoshi Suzuki. False HDAC inhibition by aurone compound. Chemical & Pharmaceutical Bulletin, 64, 1124-1128, 2016.
24. Taeko Kakizawa, Tamio Mizukami, Yukihiro Itoh, Makoto Hasegawa, Ryuzo Sasaki, Takayoshi Suzuki. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Bioorganic & Medicinal Chemistry Letters, 25, 1193-1195, 2016.
25. Yukihiro Itoh, Keisuke Aihara, Paolo Mellini, Toshifumi Tojo, Yosuke Ota, Hiroki Tsumoto, Viswas Raja Solomon, Peng Zhan, Miki Suzuki, Daisuke Ogasawara, Akira Shigenaga, Tsubasa Inokuma, Hidehiko Nakagawa, Naoki Miyata, Tamio Mizukami, Akira Otaka, and Takayoshi Suzuki. Identification of SNAIL1 Peptide-Based Irreversible Lysine Specific Demethylase 1-Selective Inactivators. Journal of Medicinal Chemistry, 59, 1531-1544, 2016.
26. Yukihiro Itoh, Hideyuki Sawada, Miki Suzuki, Toshifumi Tojo, Ryuzo Sasaki, Makoto Hasegawa, Tamio Mizukami, Takayoshi Suzuki. Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells. ACS Medicinal Chemistry Letters, 6, 665-670, 2015.
27. Taeko Kakizawa, Yusuke Ota, Yukihiro Itoh, Hiroki Tsumoto, Takayoshi Suzuki. Histone H3 peptide based LSD1-selective inhibitors. Bioorganic & Medicinal Chemistry Letters, 25, 1925-1928, 2015.
28. Mohammed Naseer Ahmed Khan, Hiroki Tsumoto, Yukihiro Itoh, Yosuke Ota, Miki Suzuki, Daisuke Ogasawara, Hidehiko Nakagawa, Tamio Mizukami, Naoki Miyata, Takayoshi Suzuki. Design, synthesis, and biological activity of N-alkylated analogue of NCL1, a selective inhibitor of lysine-specific demethylase 1. MedChemComm, 6, 407-412, 2015.
29. Prima R. Tatum, Hideyuki Sawada, Yosuke Ota, Yukihiro Itoh, Peng Zhan, Naoya Ieda, Hidehiko Nakagawa, Naoki Miyata, Takayoshi Suzuki. Identification of novel SIRT2-selective inhibitors using a click chemistry approach. Bioorganic & Medicinal Chemistry Letters, 24, 1871-1874, 2014.
30. Hiromi Sekizawa, Kazuma Amaike, Yukihiro Itoh, Takayoshi Suzuki, Kenichiro Itami, Junichiro Yamaguchi. Late-Stage C-H Coupling Enables Rapid Identification of HDAC Inhibitors: Synthesis and Evaluation of NCH-31 Analogues. ACS Medicinal Chemistry Letters, 5, 582-586, 2014.
31. Yukihiro Itoh, Daisuke Ogasawara, Yosuke Ota, Tamio Mizukami, Takayoshi Suzuki. Synthesis, LSD1 Inhibitory Activity, and LSD1 Binding Model of Optically Pure Lysine-PCPA Conjugates. Computational and Structural Biotechnology Journal, 9, e201402002, 2014.
32. Takayoshi Suzuki, Nobusuke Muto, Masashige Bando, Yukihiro Itoh, Ayako Masaki, Masaki Ri, Yosuke Ota, Hidehiko Nakagawa, Shinsuke Iida, Katsuhiko Shirahige, Naoki Miyata. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. ChemMedChem, 9, 657-664, 2014.
33. Takayoshi Suzuki, Hiroki Ozasa, Yukihiro Itoh, Peng Zhan, Hideyuki Sawada, Koshiki Mino, Louise Walport, Rei Ohkubo, Akane Kawamura, Masato Yonezawa, Yuichi Tsukada, Anthony Tumber, Hidehiko Nakagawa, Makoto Hasegawa, Ryuzo Sasaki, Tamio Mizukami, Christopher J. Schofield, Naoki Miyata. Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity. Journal of Medicinal Chemistry, 56, 7222-7231, 2013.
34. Yuji Matsuya, Yuta Kobayashia, Sayumi Uchida, Yukihiro Itoh, Hideyuki Sawada, Takayoshi Suzuki, Naoki Miyata, Kenji Sugimoto, Naoki Toyooka. Search for a Novel SIRT1 Activator: Structural Modification of SRT1720 and Biological Evaluation. Bioorganic & Medicinal Chemistry Letters, 23, 4907-4910, 2013.
35. Daisuke Ogasawara, Yukihiro Itoh, Hiroki Tsumoto, Taeko Kakizawa, Koshiki Mino, Kiyoshi Fukuhara, Hidehiko Nakagawa, Makoto Hasegawa, Ryuzo Sasaki, Tamio Mizukami, Naoki Miyata, Takayoshi Suzuki. Lysine-Specific Demethylase 1-Selective Inactivators Based on Protein-Targeted Drug Delivery Mechanism. Angewandte Chemie International Edition, 52, 8620-8624, 2013.
36. Takayoshi Suzuki, Yuki Kasuya, Yukihiro Itoh, Yosuke Ota, Peng Zhan, Kaori Asamitsu, Hidehiko Nakagawa, Takashi Okamoto, Naoki Miyata. Identification of Highly Selective and Potent Histone Deacetylase 3 Inhibitors Using Click Chemistry-Based Combinatorial Fragment Assembly, PLoS ONE, 8, e68669, 2013.
37. Takayoshi Suzuki, Yosuke Ota, Masaki Ri, Masashige Bando, Aogu Gotoh, Yukihiro Itoh, Hiroki Tsumoto, Prima R. Tatum, Tamio Mizukami, Hidehiko Nakagawa, Shunsuke Iida, Ryuzo Ueda, Katsuhiko Shirahige, Naoki Miyata. Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries. Journal of Medicinal Chemistry, 55, 9562-9575, 2012.
38. Takayoshi Suzuki, Mohammed Naseer Ahmed Khan, Hideyuki Sawada, Erika Imai, Yukihiro Itoh, Katsura Yamatsuta, Natsuko Tokuda, Jun Takeuchi, Takuya Seko, Hidehiko Nakagawa, and Naoki Miyata. Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin 2-selective Inhibitors. Journal of Medicinal Chemistry, 55, 5760-5773, 2012.
39. Yukihiro Itoh, Minoru Ishikawa, Risa Kitaguchi, Keiichiro Okuhira, Mikihiko Naito, Yuichi Hashimoto. Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorganic & Medicinal Chemistry Letters, 22, 4453-4457, 2012.
40. Yukihiro Itoh, Risa Kitaguchi, Minoru Ishikawa, Mikihiko Naito, Yuichi Hashimoto. Design, Synthesis and Biological Evaluation of Nuclear Receptor-degradation Inducers. Bioorganic & Medicinal Chemistry, 19, 6768-6778, 2011.
41. Yukihiro Itoh, Minoru Ishikawa, Risa Kitaguchi, Shinichi Sato, Mikihiko Naito, Yuichi Hashimoto. Development of target protein-selective degradation inducer for protein knockdown. Bioorganic & Medicinal Chemistry, 19, 3229-3241, 2011.
42. Keiichiro Okuhira, Nobumichi Ohoka, Kimie Sai, Tomoko Nishimaki-Mogami, Yukihiro Itoh, Minoru Ishikawa, Yuichi Hashimoto, Mikihiko Naito. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Letters, 585, 1147-1152, 2011.
43. Shohei Hamada, Takayoshi Suzuki, Koshiki Mino, Koichi Koseki, Felix Oehme, Ingo Flamme, Hiroki Ozasa, Yukihiro Itoh, Daisuke Ogasawara, Haruka Komaarashi, Aiko Kato, Hiroki Tsumoto, Hidehiko Nakagawa, Makoto Hasegawa, Ryuzo Sasaki, Tamio Mizukami, Naoki Miyata. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. Journal of Medicinal Chemistry, 53, 5629-5638, 2010.
44. Yukihiro Itoh, Minoru Ishikawa, Mikihiko Naito M, Yuichi Hashimoto. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. Journal of the American Chemical Society, 132, 5820-5826, 2010.
45. Shohei Hamada Tae-Dong Kim, Takayoshi Suzuki, Yukihiro Itoh, Hiroki Tsumoto, Hidehiko Nakagawa, Ralf Janknechtb, Naoki Miyata. Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 19, 2852-2855, 2009.
46. Takayoshi Suzuki, Sou-ichi Igari, Akira Hirasawa, Mie Hata, Masaji Ishiguro, Hiroki Fujieda, Yukihiro Itoh, Tatsuya Hirano, Hidehiko Nakagawa, Michitaka Ogura, Makoto Makishima, Gozoh Tsujimoto, Naoki Miyata. Identification of GPR120-selective agonists derived from PPAR? agonists. Journal of Medicinal Chemistry, 51, 7640-7644, 2008.
47. Yukihiro Itoh, Takayoshi Suzuki, Akiyasu Kouketsu, Nobuaki Suzuki, Satoko Maeda, Minoru Yoshida, Hidehiko Nakagawa, Naoki Miyata. Design, Synthesis, Structure-Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6 Inhibitors. Journal of Medicinal Chemistry, 50, 5425-5438, 2007.
48. Takayoshi Suzuki, Shinya Hisakawa, Yukihiro Itoh, Nobuaki Suzuki, Katsumasa Takahashi, Masatoshi Kawahata, Kentaro Yamaguchi, Hidehiko Nakagawa, Naoki Miyata. Design, synthesis and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 4208-4212, 2007.
49. Takayoshi Suzuki, Shinya Hisakawa, Yukihiro Itoh, Sakiko Maruyama, Mineko Kurotaki, Hidehiko Nakagawa, Naoki Miyata. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. Bioorganic & Medicinal Chemistry Letters, 17, 1558-1561, 2007.
50. Takayoshi Suzuki, Akiyasu Kouketsu, Yukihiro Itoh, Shinya Hisakawa, Satoko Maeda, Minoru Yoshida, Hidehiko Nakagawa, Naoki Miyata. Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate. Journal of Medicinal Chemistry, 49, 4809-4812, 2006.

1. Yuri Takada, Yasunobu Yamashita, Yukihiro Itoh, Takayoshi Suzuki. Medicinal Chemistry Research on Targeting Epigenetic Complexes. Journal of Synthetic Organic Chemistry Japan, in press, 2022.
2. Yukihiro Itoh, Yuri Takada, Yasunobu Yamashita, Takayoshi Suzuki. Recent progress on small molecules targeting epigenetic complexes. Current. Opinion in Chemical Biology, 67, 102130, 2022.
3. Yukihiro Itoh, Takashi Kurohara, Takayoshi Suzuki. N+-C-H…O Hydrogen Bonds in Protein-Ligand Complexes and their Application to Drug Design. Journal of Synthetic Organic Chemistry Japan, 78, 71151-1162, 2020.
4. Yukihiro Itoh. Drug Discovery Researches on Modulators of Lysine-Modifying Enzymes Based on Strategic Chemistry Approaches. Chemical and Pharmaceutical Bulletin, 68, 34-45, 2020.
5. Yukihiro Itoh. Chemical Protein Degradation Approach and its Application to Epigenetic Targets. The Chemical Record, 2018, 9, 1681-1700.
6. Yukihiro Itoh and Takayoshi Suzuki. “Drug” Discovery with the Help of Organic Chemistry. Yakugaku Zasshi, 137, 283-292, 2017.
7. Yukihiro Itoh and Takayoshi Suzuki. Molecular Technology for Controlling Epigenetics: Regulation of Histone Acetylation and Methylation by Small Molecules. Journal of Synthetic Organic Chemistry, Japan. 74, 441-452, 2016.
8. Peng Zhan, Yukihiro Itoh, Takayoshi Suzuki, Xinyong Liu. Strategies for the Discovery of Target-specific or Isoform-selective Modulators. Journal of Medicinal Chemistry, 58, 7611-7633, 2015.
9. Peng Zhan, Yu’ning Song, Yukihiro Itoh, Takayoshi Suzuki, Xinyong Liu. Recent Advances in the Structure-based Rational Design of TNKSIs. Molecular Biosystems, 10, 2783-2799, 2014.
10. Yukihiro Itoh, Naoki Miyata, Takayoshi Suzuki. Target-guided Synthesis: Medicinal Chemistry Strategy to Allow Target Enzymes Themselves to Synthesize their Own Inhibitors. Journal of Synthetic Organic Chemistry Japan, 72, 702-716, 2014.
11. Yukihiro Itoh, Takayoshi Suzuki, Naoki Miyata. Small-molecular modulators of cancer-related epigenetic mechanisms. Molecular BioSystems, 9, 873-896, 2013.
12. Yukihiro Itoh, Takayoshi Suzuki, Naoki Miyata. Isoform Selective Histone Deacetylase Inhibitors. Current Pharmaceutical Design, 14, 529-544, 2008.

1. Tomohiro Kozako, Yukihiro Itoh, Shin-ichiro Honda, and Takayoshi Suzuki. Epigenetic Control Using Small Molecules in Cancer. Approaching Complex Diseases (Ed. Bizzarri Mariano), Springer International Publishing, 111–148 (2020).

1. 鈴木孝禎、伊藤幸裕、三宅由花、児玉英彦、鈴間喜教、内田周作 「KDM5C阻害剤及び抗うつ剤」 特願2019-106166.
2. 鈴木孝禎、伊藤幸裕、東條敏史、内田周作　「ヒストン脱アセチル化酵素阻害剤」特願2018-108464.
3. 鈴木孝禎、伊藤幸裕、太田庸介 「抗がん剤デリバリー分子」特願2015-198860伊丹健一郎、山口潤一郎、荒木未紗保、鈴木孝禎、伊藤幸裕、太田庸介、酒井敏行、曽和義広、宮村伸「γターン構造を有する化合物及びそれを用いたLSD1阻害剤」 特願2016-065756 .
4. 鈴木孝禎、伊藤幸裕、太田庸介 「抗がん剤デリバリー分子」特願2015-198860
5. 鈴木孝禎、伊藤幸裕、宮田直樹、飯田真介、李政樹「ヒドロキサム酸誘導体及びHDAC8阻害剤」 特願2014-139425.
6. Takayoshi Suzuki, Yukihiro Itoh, Daisuke Ogasawara, Naoki Miyata, Tamio Mizukami, Ryuzo Sasaki, Akifumi Takaori, and Masahiro Kawahara. Lsd1-selective inhibitor having lysine structure. PCT Int. Appl. (2014), WO 2014084298.

1. 伊藤幸裕　鈴木孝禎　モダリティー多様化時代における低分子創薬の新たな視点　KDM5Cを標的とした創薬化学研究を例として　ファルマシア　57, 651-655, 2021.
2. 伊藤幸裕　若手研究者からのメッセージ　日本化学会倍テクノロジー部会ニュースレター　24, 16-21, 2021.
3. 伊藤幸裕　金属イオン活性型in situクリック反応によるKDM5C阻害薬の同定　Newsletter-生体機能関連化学部会 35, 2, 6-11, 2020.
4. 伊藤幸裕、鈴木孝禎　標的タンパク質自身に阻害薬をつくらせる！―短時間で薬の候補を見つける創薬手法　化学 75, 40–44, 2020.
5. 伊藤幸裕　BOOKS紹介：「がん」はなぜできるのか　そのメカニズムからゲノム医療まで　MEDCHEM NEWS 29, 138, 2019.
6. 伊藤幸裕、太田庸介、鈴木孝禎　エピジェネティクス創薬：抗がん剤から他の疾患治療薬へ　MEDCHEM NEWS 27, 184-189, 2017.
7. 太田庸介、伊藤幸裕、鈴木孝禎　LSD1高発現がん細胞を標的としたドラッグデリバリー分子の開発　MEDCHEM NEWS 26, 84-89, 2016.
8. 伊藤幸裕　論文紹介「気になった論文」　生化学研究レター 50, 27-29, 2015.
9. 伊藤幸裕、鈴木孝禎　エピジェネティクスを操る小分子化合物 ファルマシア　50, 1107-1111, 2014.
10. 伊藤幸裕、鈴木孝禎　遺伝子発現を制御する合成有機小分子―ヒストンメチル化にかかわるエピジェネティクス創薬　化学 68, 68-69, 2013.
11. 伊藤幸裕　薬のオフ・ターゲットや有害反応は予測できるのか？ ファルマシア　49, 72, 2013.
12. 伊藤幸裕、鈴木孝禎、宮田直樹. HDAC6選択的阻害薬. 医学のあゆみ、医師薬出版、224, 71-74, 2008.
13. 鈴木孝禎、伊藤幸裕、宮田直樹. ヒストン脱アセチル化酵素を分子標的とした抗がん剤の探索研究. Pharma VISION NEWS、日本薬学会薬学研究ビジョン部会、10, 12-16, 2007 (September 2007).